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Aims: Patients with permanently increased risk of sudden cardiac death (SCD) can be
protected by implantable cardioverter defibrillators (ICD). If an ICD must be removed
due to infection, for example, immediate reimplantation might not be possible or indi-
cated. The wearable cardioverter defibrillator (WCD) is an established, safe and effec-
tive solution to protect patients from SCD during this high-risk bridging period. Very
few economic evaluations on WCD use are currently available.
Methods: We conducted a systematic review to evaluate the available evidence of
WCD in patients undergoing ICD explant/lead extraction. Additionally, a decision
model was developed to compare use and costs of the WCD with standard therapy
(in-hospital stay). For this purpose, a cost-minimization analysis was conducted, and
complemented by a one-way sensitivity analysis.
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Results: In the base case scenario, the WCD was less expensive compared to stan-
dard therapy. The cost-minimization analysis showed a cost reduction of €1782 per
patient using the WCD. If costs of standard care were changed, cost savings associ-
ated with the WCD varied from €3500 to €0, assuming costs for standard care of
€6800 to €3600.
Conclusion: After ICD explantation, patients can be safely and effectively protected
from SCD after hospital discharge through WCD utilization. Furthermore, the use of
a WCD for this patient group is cost saving when compared to standard therapy.
K E YWORD S
cost-minimization analysis, health technology assessment, ICD explant, sudden cardiac death,
ventricular arrhythmia, wearable cardioverter defibrillator
1 | INTRODUCTION
Implantable cardioverter defibrillator (ICD) use in primary and secondary
prevention of sudden cardiac death (SCD) has been the standard of care
for many years. Device explantation is necessary if lead or pocket infec-
tion, lead fracture or lead malfunctions occur.1–3 Immediate
reimplantation is not always possible or even indicated. Leading national
and international cardiology societies recommend ICD reimplantation
only after complete eradication of the responsible germ.4–7 Mortality
after device removal with simultaneous antibiotic therapy ranges
between 8 and 26.9%. If patients are treated with antibiotic therapy
alone, this range increases to 31–66%.8 Early reimplantation can result
in recurrent infection. At the same time, there is a substantial risk of
ventricular tachycardia (VT) or ventricular fibrillation (VF) events leading
to SCD in these patients, since this patient group is characterized by an
established and permanent risk.9–11 Several weeks of inpatient monitoring
would be indicated, but this is neither economically attractive nor reason-
able for patients in terms of quality of life due to complications such as
thrombosis, nosocomial infection, and psychological stress. At the same
time, associated costs are increasing globally, which corresponds to the
overall increase in the rates of ICD implantations and multiplying device
and lead replacements over the years. Inpatient hospital stay is the stan-
dard pathway for patients after ICD extraction.
The incidence of cardiovascular implantable electronic device
infections is increasing faster than the device implantation rate.
Between 1993 and 2008, an increase in infections ranging from 96 to
210% was reported.2,8 Overall, this leads to a considerable burden on
healthcare systems. The management of patients waiting for an ICD
reimplantation should therefore be individualized, safe and effective,
as well as economically sustainable.
The wearable cardioverter defibrillator (WCD) has the potential
for being a useful bridging tool to cover the time-period in which
patients are normally unprotected as they wait for their infection to
resolve.
The WCD is a noninvasive external defibrillator that continuously
records and analyzes ECG sequences. In case potentially lethal VT/VF
episodes occur, up to five treatment shocks can be applied per
treatment sequence by electrodes integrated in the garment. The time
between the detection of an arrhythmia and the delivery of the treat-
ment shock is generally less than 1 min. Recorded episodes as well as
patient compliance reports are stored on a web-based server
(LifeVest Network) which can be accessed by the treating physician
via personalized login data. Instead of inpatient monitoring with a
manual defibrillation option, the WCD can effectively and systemati-
cally protect patients from SCD outside of the hospital.
The range of WCD use recommended by cardiology guidelines
includes patients after ICD extraction, as well as for various primary
and secondary prevention indications such as patients after myocar-
dial infarction with an left ventricular ejection fraction (LVEF) dysfunc-
tion (≤35%), and patients with myocarditis or transient causes of
LVEF dysfunction.4–7
Despite proven safety and efficacy, there is still little data on the
economic impact of WCD use, especially in patients following ICD
explant due to infection. We therefore decided to perform a literature
review to summarize the evidence related the efficacy, safety, and
compliance of the WCD in patients after ICD explantation and to per-
form a cost-minimization analysis to assess the economic impact asso-
ciated with WCD use compared to the standard therapy.
2 | METHODS
2.1 | Literature search
The EUnetHTA health technology assessment (HTA) core model
(EUnetHTA 2015) was used as a guideline for the literature search.
Clinical, epidemiological, and economic aspects were considered.
Electronic databases (Medline, Pubmed, and Web of Science)
were used for the literature search. Clinical and economic keywords
related to ICD explantation, its treatment options, health outcomes,
consequences for health-related quality of life (HRQoL), and its eco-
nomic implications were used. The search was performed using index/
MeSH (Medical Subject Heading) and strings. Studies were selected
based on the included indications, the age of the subjects, the year of
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publication (2008 and later) and the type of publication. We consid-
ered retrospective and prospective studies, randomized controlled tri-
als, reviews, guidelines, and practice guides. Furthermore, studies on
HRQoL in patients with sudden cardiac arrest (SCA) were used.
All publications were analyzed for efficacy, safety, and compliance
in the target population, and duplicates were removed. Furthermore,
all publications not containing information on the target population or
the relevant aspects were excluded.
2.2 | Cost minimization analysis overview
We developed a decision-analytical Markov model to simulate the
long-term clinical pathway and costs associated with the management
of patients that required an ICD explantation due to infection. The
model was used to perform a cost-minimization analysis comparing
two alternative treatment options: (1) WCD and (2) Standard of care
in Italy, in order to understand the relative economic impact.
(Figure 1) The decision to perform a cost-minimization analysis was
based on the conservative assumption that WCD and the standard of
care in Italy had the same efficacy. The standard of care was hospitali-
zation in a low-intensity hospital after ICD explantation until the
infection is cured and reimplantation is performed. Low-intensity hos-
pitals are hospitals dedicated to patients that have a lower risk com-
pared to patients treated in intensive care, but liable to develop
complications and in need of close monitoring much more than the
standard care at home. They were established in Italy to meet
the increasing need of long in-hospital stay, which was previously
managed in acute hospitals, and are used for patients that do not need
an acute management.
The choice of a cost-minimization analysis was made to perform a
conservative analysis. The assumption of same efficacy, which is
required to perform a cost-minimization analysis instead of a cost-
effectiveness analysis, was considered conservative due to the evi-
dence available that suggests a possible higher efficacy of WCD.10
Hospitalization in a low-intensity hospital does not guarantee that
patients are adequately protected from SCD unless they are in a mon-
itor bed or on an intensive care unit.
To perform the cost-minimization analysis, we retrieved data per-
forming an extensive literature review. (Supplement Table 1) We
discounted the costs at an annual rate of 3%.12,13 The analyses were
conducted from the perspective of the Italian National Health Service
(NHS) and the results were presented in Euro (€). (Table 1).
2.3 | Decision analytic model structure
We built a state-transition Markov model using Microsoft Excel to
assess the overall costs associated with the use of WCD, using a
F IGURE 1 Markov model
TABLE 1 Base-case scenario
Treatments Cost Cost discounted
WCD €105 175.35 €86 035.52
Standard of care €106 997.92 €87 817.92
Δ Cost Δ Cost discounted
WCD versus standard of care €1822.58 €1782.40
Note: Δ, delta/difference.
Abbreviation: WCD, wearable cardioverter defibrillator.
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lifetime time horizon and monthly cycle. A hypothetical cohort of
patients with ICD removed due to infection, with a mean age
of 61 years (Supplementary Table 4) can receive the WCD after ICD
removal or can be hospitalized in a low-intensity hospital during the
first monthly simulation cycle. Patients stay in this health state for
1 month; after this time period, we assumed the resolution of infec-
tion and the implantation of a new ICD. The new ICD implantation
could be successful or result in procedural death. Patients with ICD
entered in the post-ICD health state, where they could be hospitalized
for heart failure, experience new ICD infection, ICD generator
replacement, and die from cardiac death or other causes.
2.4 | Data input: Clinical data
Clinical data are reported in Supplementary Table 4. Based on the
conservative approach of the cost-minimization analysis, we assumed
a comparable WCD effectiveness to the standard therapy in Italy. The
effectiveness of the intervention was presented based on the inci-
dence of SCA in the first month after ICD extraction and WCD event
survival rates of 85.5%. Event survival rate was defined as SCA rate
due to VT/VF events in the context of all SCA events including, for
example, asystole, with a 100% termination-success rate of VT/VF
events by the WCD.10,14 Cardiac and noncardiac deaths were pres-
ented and analyzed separately for the assessment of long-term mor-
tality after ICD reimplantation, in accordance with Woo et al.15
Furthermore, the mortality risk was split and separately assessed
according to general (noncardiac) causes of death, which increase with
age, and specific mortality risks, which are particularly present in
patients with heart disease. Data on general population mortality
were taken from the Italian Institute of Statistics (ISTAT).
In order to assess excess mortality in patients with ICDs, total
mortality in the ICD group and the prevalence of SCD were estimated
from the SCD-HeFT (Sudden Cardiac Death in Heart Failure) and
MADIT-II (Multicenter Automatic Defibrillator Implantation Trail)
studies.16,17 During the simulation of the model, excess cardiac mor-
tality remained constant, allowing the mortality of the general popula-
tion to increase with age. Thus, the proportion of SCD in the overall
mortality risk decreased over time.
Furthermore, the mortality risk associated with ICD implantation
and ICD side effects was integrated into the model.18–20 The probabil-
ities of lead failure or ICD infection were estimated based on publi-
shed registry data.18–23
2.5 | Data input: Costs
Cost data are reported in Supplementary Table 4. For the simulation
30 days after ICD explant, we considered WCD costs, ICD
reimplantation costs, as well as costs for inpatient stay, here consid-
ered the standard therapy. WCD costs were estimated to be €3600,
according to the Italian average price (provided by ZOLL Medical
Italia srl), and the cost of inpatient therapy in a low-intensity hospital
was estimated to be €5250 (€250 daily hospital costs and 21 days hos-
pital stay). Costs for ICD implantation, as well as costs for possible
subsequent complications were taken from the Italian DRG system.
Accordingly, the costs of HF hospital stay for ICD patients were calcu-
lated. A mean ICD battery life of 5 years was assumed, excluding the
possibility of battery failure within the first 2 years.24,25 The mean
monthly cost of a patient after ICD implantation was determined
based on the results of Smith et al.26
2.6 | Analysis
We conducted a base case analysis to assess the costs of WCD ther-
apy and standard of care, as well as the difference in total costs asso-
ciated with these interventions.
We also performed a sensitivity analysis assessing the impact of
WCD and hospitalization cost reducing and or increasing the parame-
ter from 30% to +30%. This analysis provides valuable information
to understand the impact of treatment cost on the results and gives
the possibility to understand the economic impact in scenarios where
WCD and standard of care have different costs compared to what
was assumed in our base case analysis. The hospitalization cost of
€5250, used in our base case analysis, was estimated by multiplying
the daily cost of hospitalization (€250) by 21 days of hospital length
of stay. Based on this cost estimation, assessing a reduction of 30%
of hospitalization cost means reducing the day cost of 30% (from
€250 to €175 per day) or reducing the length of stay from 21 to
15 days. Same meaning is associated to increasing the hospitalization
cost by 30% (from €250 to €325 per day or hospital length of stay
from 21 to 27 days).
Finally, a one-way sensitivity analysis was carried out to confirm
the reliability of the results and to determine the influence of the indi-
vidual parameters.
Since our research was based on a systematic review of published
literature, with no direct patient involvement, ethical approval was
not required and patient consent was not applicable.
3 | RESULTS
3.1 | WCD efficacy, safety, and compliance
Twenty-six original studies were analyzed to evaluate the efficacy,
safety, and compliance of the WCD in patients after ICD explantation.
A total of 14 studies were included in the analyses, including our tar-
get population explanted ICD. Thirteen studies were retrospective,
and two studies were prospective. (Suppl. Table S1).8,11,14,27–38 Three
studies had an exclusive focus on patients after ICD removal.8,11,31 In
addition, the only available RCT for WCD use was consulted to verify
the results of the registry data.39 In some studies with a mixed patient
population, no specific results could be determined for our population.
Overlaps between the studies were excluded. All included studies
considered effectiveness, safety, and compliance. The comparison of
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the studies' results is difficult due to differences in design and obser-
vation periods. (Supplement Tables 2–3) However, it can be con-
cluded for all evaluated studies that the WCD is able to protect
patients safely and effectively from SCD after ICD removal. The rate
of inappropriate shocks was extremely low (<0.6%) in all stud-
ies.8,11,14,27–38,40 In almost all evaluated studies, patients demon-
strated a compliance >20 h per day. Also the as-treated analysis of
the VEST trial41 stressed how compliance to WCD, in terms of hours
in a day actually wearing the device, is a key factor in conditioning the
effect of this intervention on outcomes and this implies that patient
education and selection are crucial.
According to Tanawuttiwat et al., mortality is 8.2% in patients
after device removal due to infection. The authors described the
WCD as useful in protecting patients in the bridging period after
removal until reimplantation.8 Ellenbogen et al. concluded that the
WCD provides physicians with more flexibility in their treatment of
patients after ICD explantation by protecting them during the high-
risk period, and by allowing time for the determination of a long-term
risk management strategy.11
3.2 | WCD cost-minimization in patients after ICD
explantation due to infection in Italy
We conducted a cost-minimization analysis for the WCD in compari-
son to the standard therapy (low-intensity inpatient hospitalization).
In the basic scenario, WCD therapy proved not only to be cost-
effective, but cost saving. Cost savings of €1782 per patient were
gained when using the WCD (Table 1). Both the costs of the WCD
and the costs of standard therapy influenced the results. (Figures 2
and 3) In the Figure 2, we assessed the impact of different WCD
prices on the possible cost savings associated to WCD. Assuming
WCD costs ranging from €2700 to €4500, the WCD remained cost
saving with a cost reduction of €2800 using a WCD price of €2700
and of €810 using a price of €4500. The same analysis was performed,
modifying the standard of care costs (Figure 3). In this analysis, the
WCD costs were fixed. The WCD presents here as well with cost sav-
ings, even if we reduced the standard of care costs to €3600.
(Figure 3) When increasing the standard of care costs to €6800, cost
savings of €3500 were associated to WCD. In the one-sided-
sensitivity analysis, WCD costs and standard therapy were confirmed
to be the main influencing factors on the results of the cost minimiza-
tion analysis. (Supplementary Figure 1).
4 | DISCUSSION
The proper care of patients after infection-related ICD removal is a
challenge for many reasons. The substantial and persistent risk for
SCD is already confirmed in all ICD patients. After ICD removal, the
patient is unprotected from their risk of SCD, due to the respective
underlying disease. This risk even increases from the infection and
explant procedure itself. The consequences of a survived, but inade-
quately treated SCA can lead to considerable costs and impairments
F IGURE 2 WCD cost-minimization in
relation to WCD cost. Variation of WCD
cost with stable standard of care costs.
The higher the WCD costs, the lower the
difference to the costs of standard
therapy and vice versa. Within the known
renting costs range and further, there will
be savings with the WCD approach.
WCD, wearable cardioverter defibrillator
F IGURE 3 WCD cost-minimization in
relation to standard of care cost. Variation
of standard of care costs with stable
WCD costs. The higher the standard of
care costs, the greater the savings with
the WCD approach. WCD, wearable
cardioverter defibrillator
BORIANI ET AL. 1501
both on an economic and patient level.10 These costs could increase
considerably depending on the time needed for adequate therapy,
that is, defibrillation.42
Life-threatening arrhythmias usually occur unexpectedly,
unobserved, often at home and during sleep.43 The initial probability
of survival is less than 7% due to delayed defibrillation or no defibrilla-
tion at all.27,44,45 The 30-day survival rate is only 2.4%.46 Up to 50%
of SCA survivors cope with serious consequences such as long-term
severe neurological damage, cognitive impairment, depression, and
post-traumatic stress disorder.47–51 An Italian pilot study on early
defibrillation by volunteers using publicly available AEDs was able to
reduce the SCD rate, but not to the expected or desired extent.52 This
was due to the fact that most high-risk patients spend an insufficient
amount of the day in public places, and SCA is more likely to occur
at home.51
The costs incurred by SCA/SCD also represent a considerable
burden on the country-specific health care system. Weng et al. esti-
mate the costs at discharge from hospital at $32 000, with subse-
quent costs of $12 953 in the first year after SCA.53 However, the
costs and outcomes vary depending on the time of defibrillation. Van
Alem et al. calculated that in the case of defibrillation after 2 min, the
probability of survival is about 46% with costs around $20 253.
Remarkably, if defibrillation is performed just after 6 min, the proba-
bility of survival is as low as 13%, resulting in costs around €27 781.42
The earlier a patient is defibrillated, the higher the probability of
patient survival and the lower the associated costs. This, unfortu-
nately, presents a conflict with the general response times of emer-
gency medical systems (EMS), which vary between 10 and 15 min on
average in Europe.44
The back-up defibrillation therapy ensured by an ICD is the gold
standard in patients with a confirmed long-term increased risk of
SCD. If an ICD infection occurs, explantation of the device, the leads,
or both is often unavoidable, as the infection is associated with signifi-
cant mortality, morbidity and costs. The mortality rate is around
8–26%.8 The number of hospital admissions caused by cardiac device-
related infections rose from 5308 in 2003 to 9948 in 2011, and asso-
ciated costs also increased from $91 348 to $173 211, accordingly.9
The management of patients after ICD explantation is difficult, as the
patients are unprotected from their predetermined high risk of
SCD.3,54,55 Alternatives for protecting these patients are limited. The
risk of mortality due to device infection only adds to the preexisting
and predetermined risk of SCD. After explantation, patients have a
4–6% risk of experiencing a life-threatening VT/VF event.8,11 Apart
from a WCD, there are hardly any alternatives available that ade-
quately protect the patient, and are economically attractive at the
same time. Inpatient monitoring is not a feasible alternative. Early ICD
reimplantation is not recommended by the guidelines due to the high
risk of reinfection. The WCD, as a noninvasive external cardioverter
defibrillator, has been established in clinical routine for various indica-
tions in over a decade. It effectively covers the bridging time from
hospital discharge until possible device reimplantation. Efficacy,
safety, and compliance of the WCD has been confirmed in several
indications by various retro- and prospective registry data as well as
in an RCT. In conclusion, the WCD is a useful bridging tool to
reimplantation, protecting patients at risk from SCD by delivering a
timely and reliable defibrillation if and when needed. In explanted
patients, the clinical value of the WCD is not only demonstrated by
the number of terminated or avoided arrhythmic events, but also
by allowing for protected risk assessment outside of the hospital, and
the possibility to perform guideline-based reimplantations. The WCD
is therefore recommended by national and international cardiology
societies for various indications, especially for use in patients after
ICD removal due to infection.4–7
To better assess the economic significance of WCD use, three
studies published between 2015 and 2017 were analyzed. Two publi-
cations included mixed patient populations. One study focused on
patients after ICD removal. In summary, all studies showed positive
and cost-effective WCD use, although the studies differed in method,
design, investigated collective and time horizon, setting and type of
analysis.
Only few studies have been published to date which focus on the
economic implications of the WCD.
In the largest study, Healy and Carrillo developed a Markov model
for the US healthcare system to demonstrate cost-effectiveness of
WCD use in patients after ICD removal.10 They analyzed direct costs
(e.g., cost of WCD device, hospital costs, cost of laboratory tests, cost
of follow-up visits, and costs related to ICD implantation and manage-
ment) as well as indirect costs (loss of income and loss of productivity
for premature death). The starting point of the investigations was the
assumption of four possible patient management options: discharge
home with or without WCD, discharge to a skilled nursing facility
without WCD and further inpatient monitoring. The quality adjusted
life years (QALYs) and life year (LYs) gained were calculated as param-
eters of effectiveness between the alternative strategies. According
to their calculations, the Incremental Cost-Effectiveness Ratio (ICER)
of the WCD strategy as compared to unprotected patient discharge
from hospital amounted to $20 300 per LY and $26 436 per QALY
gained. In comparison to the other alternatives, the WCD proved
again to be cost effective. In fact, patient discharge to a skilled nursing
facility and in-hospital monitoring resulted in higher costs and worse
clinical outcomes. Healy and Carrillo performed a one- and two-sided
sensitivity analysis to reflect result uncertainties. The SCA event rate,
WCD treatment efficacy, and time to reimplantation had the greatest
influence on the ICER. Overall, WCD cost-effectiveness decreased
with declining SCA event rate. WCD cost-effectiveness increased
with higher WCD efficacy. If WCD efficacy of 95% or <69% was con-
sidered, the ICER was between $15 392/QALY and >$50 000/QALY.
Assuming a SCA risk of 5.6% over a two-month period, the WCD
remained cost-effective as long as the time to reimplantation was at
least 2 weeks.10
We conducted a cost-minimization analysis to further investigate
these statements. In this analysis, the WCD demonstrated cost sav-
ings of €1782 per patient, compared to the comparative therapy, fur-
ther inpatient stay. These calculations were based on the assumption
of equivalent WCD effectiveness with the standard of care (three
weeks hospital stay in a low-intensity hospital). Considering the
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results of Healy and Carillo,10 who estimated the effectiveness of
the WCD to be higher than standard therapy, our assumptions are
rather conservative, and the resulting calculations are likely an
underestimation of the potential savings. However, even with this
conservative approach, the WCD proves to be cost saving for the
Italian NHS budget. These results were confirmed in a sensitivity
analysis, and are most likely applicable to other healthcare systems
internationally as well. Even by significantly changing the WCD
costs, the analysis reported the WCD as a cost saving option with
a range from €2800 (using WCD costs of €2700) to €810 (using
WCD costs of €4500).
Some limitations must be considered when reviewing the present
analysis. The main limitation of this analysis is connected with the
absence of a direct comparison provided by a randomized controlled
trial. As there was no direct comparison between the effectiveness of
a WCD approach with in-hospital management at hand, we assumed
equal effectiveness, despite the fact that in a normal ward manual
defibrillation within few minutes cannot be guaranteed 24/7, espe-
cially during sleep of a patient, and therefore may be inferior to WCD
use. However, a specific cost-effectiveness analysis based on trial
data is needed to estimate a more precise value of the WCD in this
setting. The considered standard of care and costs were taken from
the specific Italian situation and may be adapted to other health care
systems.
Nevertheless, our cost-minimization analysis may help decision-
makers to better understand not only the clinical, but also the poten-
tial economic value of the WCD in patients after infection-related
ICD removal.
5 | CONCLUSION
The use of WCD for protecting patients at risk of SCD who require
ICD explantation is a safe and effective strategy for SCD protection,
as well as cost saving. The cost-minimization analysis demonstrated a
cost reduction of €1782 per patient using the WCD. The WCD allows
for a flexible and individualized treatment of patients after ICD
explant. Furthermore, it provides physicians with the needed time to
develop a guideline directed long-term risk management strategy for
their patients. The need for such temporary protection is justified by
the high rate of life-threatening arrhythmias caused by the underlying
disease, the infection, and the explant procedure itself. Our analysis
supports the few limited findings so far regarding the economic
impact of WCD. Additional studies may follow to further substantiate
the cost-effectiveness and cost saving potential of the WCD. For
now, however, the use of WCD in patients undergoing ICD removal is
reasonable from a clinical and economic perspective in the Italian
NHS, and quite possibly in other national health care systems as well.
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